登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
Denosumab Strategy for Liver Cancer With Bone Metastases
ClinicalTrials.gov 上登记的一项肝细胞癌开放试验,由华中科技大学同济医学院附属同济医院牵头,本站收录的另外 0 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月8日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 1
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT07537972,读取于 2026年11月8日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 6
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(6 项)收起清单
18 岁 至 75 岁;性别:不限
登记记录的入选字段
Hepatocellular carcinoma confirmed by imaging and/or histology according to current institutional diagnostic standards
入选标准第 2 条
Bone metastasis confirmed by CT, MRI, bone scintigraphy, PET-CT, or pathology
入选标准第 3 条
Prior treatment with PD-1, PD-L1, CTLA-4, or other immune checkpoint inhibitors
排除标准第 1 条
ECOG performance status 0 to 1
入选标准第 4 条
At least 1 measurable intrahepatic lesion at baseline and planned initiation of a PD-1 inhibitor-based systemic therapy
入选标准第 6 条
Pregnancy or breastfeeding, or refusal to use effective contraception when applicable
排除标准第 9 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);化验:血常规、肝肾功能;试验排除的其他疾病。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07537972,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
Age 18 to 75 years Hepatocellular carcinoma confirmed by imaging and/or histology according to current institutional diagnostic standards Bone metastasis confirmed by CT, MRI, bone scintigraphy, PET-CT, or pathology ECOG performance status 0 to 1 Child-Pugh class A or stable Child-Pugh B7 judged suitable for systemic treatment At least 1 measurable intrahepatic lesion at baseline and planned initiation of a PD-1 inhibitor-based systemic therapy Estimated life expectancy of at least 3 months Adequate organ function according to protocol-defined laboratory criteria Corrected serum calcium within the normal range, or corrected to protocol-defined range after calcium/vitamin D supplementation Completed baseline oral/dental risk assessment and willingness to avoid nonessential invasive dental procedures during the study Written informed consent and willingness to comply with study visits, questionnaires, sample collection, and follow-up排除标准:Exclusion Criteria:
Prior treatment with PD-1, PD-L1, CTLA-4, or other immune checkpoint inhibitors Receipt of denosumab or intravenous/oral bisphosphonates for tumor-related bone disease within 6 months before randomization Uncorrected hypocalcemia or severe vitamin D deficiency that cannot be corrected promptly Current or prior osteonecrosis of the jaw, jaw osteomyelitis, or high-risk dental condition requiring near-term extraction, implantation, or other invasive dental procedures that cannot be deferred Active autoimmune disease or need for systemic immunosuppressive treatment, except for low-risk conditions judged acceptable by the investigator Life-threatening bone complication within 4 weeks before randomization that is not stabilized, including unresolved spinal cord compression or clinically significant spinal instability Active infection, including uncontrolled bacterial or fungal infection, active tuberculosis, or other condition judged unsafe for systemic treatment Symptomatic or uncontrolled central nervous system metastases Pregnancy or breastfeeding, or refusal to use effective contraception when applicable Known severe hypersensitivity to denosumab or any study-related treatment component Another active malignancy, poor compliance, or any condition judged by the investigator to make study participation unsuitable
引自 ClinicalTrials.gov, NCT07537972, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07537972,读取于 2026年11月8日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。